MB 102

Drug Profile

MB 102

Alternative Names: Anti-CD123 chimeric antigen receptor T cell therapy - Mustang Bio; MB 102 - Mustang Bio; MB102

Latest Information Update: 29 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator City of Hope National Medical Center
  • Developer Mustang Bio
  • Class Antineoplastics; CAR-T cell therapies; Cell therapies; Gene therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Acute myeloid leukaemia

Most Recent Events

  • 01 Feb 2017 Mustang Bio entered into three amended and restated exclusive patent license agreements for MB 102
  • 01 Dec 2015 Phase-I clinical trials in Acute myeloid leukaemia (Second line therapy or greater; In adults; In elderly) in USA (Parentral) (NCT02159495) (Fortress Biotech pipeline, March 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top